{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 411374493
| IUPAC_name = (''RS'')-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione
| image = Mesuximide.svg
| width = 150
| chirality = [[Racemic mixture]]

<!--Clinical data-->
| tradename = Celontin
| Drugs.com = {{drugs.com|CDI|methsuximide}}
| MedlinePlus = a682028
| pregnancy_US = C
| legal_US = Rx-only
| routes_of_administration = [[Oral administration|By mouth]] ([[Capsule (pharmacy)|capsules]])

<!--Pharmacokinetic data-->
| metabolism = [[Liver|Hepatic]] ([[demethylation]] and [[glucuronidation]])
| metabolites = ''N''-desmethylmethosuximide
| elimination_half-life = 1.4–2.6 hours <small>(mesuximide)</small><br>28–38 hours <small>(active metabolite)</small>
| excretion = [[Urine]]

<!--Identifiers-->
| IUPHAR_ligand = 7228
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 77-41-8
| ATC_prefix = N03
| ATC_suffix = AD03
| PubChem = 6476
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB05246
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 6231
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0G76K8X6C0
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00404
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 697

<!--Chemical data-->
| C=12 | H=13 | N=1 | O=2
| molecular_weight = 203.237 g/mol
| smiles = O=C2N(C(=O)CC2(c1ccccc1)C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = AJXPJJZHWIXJCJ-UHFFFAOYSA-N
}}

'''Mesuximide''' (or '''methsuximide''', '''methosuximide''') is a [[succinimide]] [[anticonvulsant]] medication. It is sold as a [[racemate]] by [[Pfizer]] under the tradenames '''Petinutin''' (Switzerland)<ref name=Petinutin>{{cite web|author=Pfizer AG |year=2005 |url=http://www.pfizer.ch/internet/fr/home/products/central_nervous_system/epilepsy/petinutin_mesuximid.html |title=Petinutin (Mésuximide) |work=Official Pfizer AG Website |accessdate=August 21, 2006 |language=French |deadurl=yes |archiveurl=https://web.archive.org/web/20050422010830/http://www.pfizer.ch/internet/fr/home/products/central_nervous_system/epilepsy/petinutin_mesuximid.html |archivedate=April 22, 2005 }}</ref> and '''Celontin''' (United States).<ref name=Celontin>{{cite web | author = Pfizer Inc. | year = 2008 | url = http://labeling.pfizer.com/ShowLabeling.aspx?id=555 | title = Celontin (methsuximide capsules, USP) | work = Official Pfizer Inc. Website | accessdate = November 21, 2014 | language =  }}</ref> The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, ''N''-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.<ref>Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.</ref>

==Medical use==
is indicated for the control of [[absence seizure]]s that are refractory to other drugs.<ref name=Celontin />

==References==
{{Reflist}}

{{Anticonvulsants}}

[[Category:Anticonvulsants]]
[[Category:Succinimides]]

{{anticonvulsant-stub}}